Reply to "Letter to Dobesh et al. on lower mortality with andexanet alfa in factor Xa inhibitor-related major bleeding"
Res Pract Thromb Haemost
.
2024 Apr 27;8(4):102429.
doi: 10.1016/j.rpth.2024.102429.
eCollection 2024 May.
Authors
Paul P Dobesh
1
,
Gregory J Fermann
2
,
Mary J Christoph
3
,
Bruce Koch
3
,
Eva Lesén
4
,
Hungta Chen
3
,
Belinda Lovelace
3
,
Theresa Dettling
3
,
Mark Danese
5
,
Julie Ulloa
5
,
Sherry Danese
5
,
Craig I Coleman
6
7
Affiliations
1
Department of Pharmacy Practice and Science, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska, USA.
2
Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
3
AstraZeneca, Wilmington, Delaware, USA.
4
AstraZeneca, Gothenburg, Sweden.
5
Outcomes Insights, Agoura Hills, California, USA.
6
University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
7
Evidence-based Practice Center, Hartford Hospital, Hartford, Connecticut, USA.
PMID:
38993619
PMCID:
PMC11238041
DOI:
10.1016/j.rpth.2024.102429
No abstract available